FDA’s Project Optimus aims to transform early cancer researchNovember 14, 2023PharmacyALLAMLCMLDLBCLLeukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell Disorders
REGN1979 shows good activity in pretreated aggressive B-NHLJanuary 15, 2020DLBCLLymphoma & Plasma Cell Disorders
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomasJanuary 14, 2020Aggressive LymphomasPediatricsDLBCLLymphoma & Plasma Cell Disorders
Survival data reported from largest CAR T trial in B-cell lymphomaDecember 20, 2019Lymphoma & Plasma Cell DisordersDLBCL
Care coordination, equity can eliminate disparities for nonwhite patients with DLBCLDecember 8, 2019DLBCLLymphoma & Plasma Cell DisordersNon-Hodgkin Lymphoma
Armored CAR T cells elicit responses in NHL patientsNovember 12, 2019DLBCLLymphoma & Plasma Cell Disorders
CAR T-cell therapy found safe, effective for HIV-associated lymphomaSeptember 20, 2019Aggressive LymphomasLymphoma & Plasma Cell DisordersDLBCL
Could home care replace inpatient HSCT?September 18, 2019TransplantationDLBCLLymphoma & Plasma Cell Disorders
Study confirms prognostic impact of MYC partner gene in DLBCLSeptember 17, 2019DLBCLLymphoma & Plasma Cell Disorders
Chemo-free combo gets high response rate in relapsed or refractory DLBCLJuly 23, 2019DLBCLLymphoma & Plasma Cell Disorders
CAR T-cell therapy less effective in transformed follicular lymphomaJuly 22, 2019Lymphoma & Plasma Cell DisordersDLBCL
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCLJuly 18, 2019DLBCLLymphoma & Plasma Cell Disorders
On second thought, lenalidomide does improve DLBCL outcomesJuly 15, 2019DLBCLLymphoma & Plasma Cell Disorders
